Maryland State Retirement & Pension System Has $7.71 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• The Maryland State Retirement & Pension System increased its stake in Boston Scientific Corporation by 4.5% in Q2, holding a total of 71,745 shares worth approximately $7.71 million.
• Boston Scientific's latest quarterly earnings revealed an EPS of $0.75, exceeding estimates and reflecting a 22.8% year-over-year revenue increase to $5.06 billion.
• Institutional investors own about 89.07% of Boston Scientific's stock, indicating strong institutional interest in the company despite recent insider sales.

Maryland State Retirement & Pension System increased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,745 shares of the medical equipment provider's stock after acquiring an additional 3,059 shares during the quarter. Maryland State Retirement & Pension System's holdings in Boston Scientific were worth $7,706,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. 1248 Management LLC bought a new position in Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the 1st quarter worth approximately $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after buying an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific in the second quarter valued at approximately $37,000. Finally, Activest Wealth Management lifted its position in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 373 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.9%

Boston Scientific stock opened at $96.73 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The stock has a market capitalization of $143.33 billion, a PE ratio of 57.58, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. The business's fifty day moving average is $102.34 and its 200 day moving average is $101.96.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the firm posted $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 over the last 90 days. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BSX shares. Canaccord Genuity Group upped their target price on Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a report on Wednesday, October 1st. Truist Financial upped their target price on Boston Scientific from $125.00 to $129.00 and gave the company a "buy" rating in a report on Wednesday, October 1st. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Evercore ISI reduced their price target on Boston Scientific from $115.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.